|
|
|
|
|
|
by AvocadoPanic
157 days ago
|
|
|
The 'risk' here is often carried by publicly funded research. ~6.2 billion for glp The private 'investment' comes in manufacturing, scale and marketing. Novo Nordisk has spent 41% more on shareholder enrichment (buybacks and dividends) than on R&D over the past five years. |
|
|
So they are good stewards of their funds and know they can't deploy as much as they have? Berkshire Hathaway does the same thing.